|
Pharmaceutical Products – Medicines For First-Line Antituberculosis Agents For Continuous Therapy Of Patients With Tuberculosis For The Period 2025–2027. J04am02, Rifampicin, Isoniazid, 150Mg + 75Mg, Film-Coated Tablet,J04am06, Rifampicin, Isoniazid, Pyrazinamide, Ethambutol, 150 Mg + 75 Mg + 400 Mg + 275 Mg, Film-Coated Tablet,J04ac01, Isoniazid, 100 Mg, Film-Coated Tablet,J04ac01, Isoniazid, 300 Mg, Film-Coated Tablet,J04ab02, Rifampicin, 300 Mg, Tablet/Capsule,J04ak02, Ethambutol, 400 Mg, Film-Coated Tablet,J04ak02, Ethambutol, 100 Mg, Film-Coated Tablet,J04ak01, Pyrazinamide, 500 Mg, Tablet,J01ga01, Streptomycin Sulphate, 1 G, Powder For Solution For Injection,J04ad01, Protionamide, 250 Mg, Film-Coated Tablet,J04ab01, Cycloserine, 250 Mg, Capsule/Tablet,V07ab, Water For Injection (Solvents And Diluting Agents), 2 Ml, Vehicle For Parenteral Use
|
